Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review.

has not yet been systematically evaluated. The patients in this series responded to doses lower than the standard dosing used in other skin and systemic disorders (3.5-5 mg/kg/ day). Initial treatment response by our first patient at a low dose prompted treatment initiation at lower doses for subsequent patients in this series. Other immunosuppressive treatment approaches could also be considered for patients with refractory folliculitis decalvans, as demonstrated by our recent case series using tofacitinib. Our study is limited by small sample size and use of concomitant medication. Further studies are required to further evaluate the safety and effectiveness of cyclosporin in folliculitis decalvans as well as standardise a therapeutic dose. Our findings suggest cyclosporin may be a treatment option for folliculitis decalvans, particularly when activity persists despite antibacterial treatment or conventional immunosuppression.